Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation

Yonsei University350 enrolled

Overview

This study aims to investigate whether statin therapy can help prevent recurrence of hepatocellular carcinoma (HCC) in transplant recipients who had liver transplantation for HCC. Multiple logistic regression analysis will be performed to evaluate the association between statin therapy and the risk of HCC recurrence after LT.

Study Type

OBSERVATIONAL

Enrollment

350

Conditions

Hepatocellular Carcinoma

Interventions

StatinDRUG

Patients who used statins over 1 month for the treatment of dyslipidemia after LT were enrolled as statin group.

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who received LT at the Severance Hospital from 2006 to 2016. Exclusion Criteria: * early postoperative mortality (defined as death within 2 months after LT without signs of tumor recurrence) * patient with distant lymph node metastasis confirmed within 1 month after LT * Patients younger than 20 years of age * patients who had LT for cirrhosis without confirmed HCC

Locations (1)

Division of Endocrinology and Metabolism Department of Internal Medicine, Yonsei University College of Medicine

Seoul, South Korea

Outcomes

Primary Outcomes

A new lesion with radiographic features compatible with HCC was defined as recurrence of HCC.

Usually, liver CT is performed at 1 week, 1 month, 6 months, and every year until 5 years after surgery. Afterwards, liver CT is performed at 2-year intervals. Measurement of blood tumor markers \[AFP and prothrombin induced by vitamin K absence-II\] is performed every month for 6 months after discharge from the hospital and every 3 months thereafter. Additional liver CT, liver magnetic resonance imaging, or positron emission tomography-CT is performed when elevated tumor markers or suspicious lesions were noted. A new lesion with radiographic features compatible with HCC is defined as recurrence of HCC based on the reports of specialist in radiology.

Time frame: up to December, 2017

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.